Русский
Hiv–protease Inhibitor Darunavir In The Schemes Of Antiretroviral Therapy Of The First Line
A.V. Kravchenko С.2530
HIV–protease inhibitor darunavir in the schemes of antiretroviral therapy of the first line
The results of open-label, randomized comparative phase III trial (ARTEMIS) concerned with evaluation the possibility of use of HIV protease inhibitor Darunavir, "enhanced" by ritonavir (DRV/r) as a component of antiretroviral therapy (ART) of the first line in patients previously not receiving ART, are presented. After 96 weeks of therapy, the ART scheme with DRV/r was more effective than the ART scheme with lopinavir/ritonavir (LPV/r), since the proportion of patients with HIV RNA level below 50 copies/ml were 79 and 71% respectively. The use of DRV/r was more effective in patients with initially high viral load (more than 100 thousand copies/ml) or low number of CD4-lymphocytes (less than 200 cells/ml). ARTEMIS study demonstrated good tolerability of both schemes ART for 96 weeks of treatment. Due to the development of adverse events, treatment was discontinued only in 4% of patients receiving DRV/r, and in 9% of patients receiving LPV/r.
The results of open-label, randomized comparative phase III trial (ARTEMIS) concerned with evaluation the possibility of use of HIV protease inhibitor Darunavir, "enhanced" by ritonavir (DRV/r) as a component of antiretroviral therapy (ART) of the first line in patients previously not receiving ART, are presented. After 96 weeks of therapy, the ART scheme with DRV/r was more effective than the ART scheme with lopinavir/ritonavir (LPV/r), since the proportion of patients with HIV RNA level below 50 copies/ml were 79 and 71% respectively. The use of DRV/r was more effective in patients with initially high viral load (more than 100 thousand copies/ml) or low number of CD4-lymphocytes (less than 200 cells/ml). ARTEMIS study demonstrated good tolerability of both schemes ART for 96 weeks of treatment. Due to the development of adverse events, treatment was discontinued only in 4% of patients receiving DRV/r, and in 9% of patients receiving LPV/r.
Similar Articles
